{"id":"W4323320185","doi":"10.1038/s41591-023-02222-w","title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Lipid metabolism and disorders","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Université de Montréal","funders":"Kowa Company; Amarin Corporation; Esperion Therapeutics; Regeneron Pharmaceuticals; University of Pennsylvania; Amgen; BioClinica; Eli Lilly and Company","keywords":"Hypertriglyceridemia; Lipoprotein lipase; Medicine; Randomized controlled trial; Lipase; Internal medicine; Genetics; Endocrinology; Bioinformatics; Biology; Biochemistry; Enzyme; Triglyceride; Cholesterol","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001872884,0.0004174046,0.001976453,0.0007812695,0.00009027401,0.00001454039,0.0001643824,0.0004859047,0.0008774301],"category_scores_gemma":[0.007669328,0.0002154523,0.0001559269,0.002252022,0.0003885142,0.0001583856,0.00003730823,0.001251337,0.00009210084],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007669462,"about_ca_system_score_gemma":0.0007605545,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003898429,"about_ca_topic_score_gemma":0.0002491356,"domain_scores_codex":[0.9968282,0.0002923797,0.0008029632,0.0005866636,0.0009631978,0.0005265895],"domain_scores_gemma":[0.9978215,0.0008376581,0.0002302834,0.0005647939,0.0002136683,0.0003321318],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9636537,0.000431781,0.0001410283,0.0002165784,0.000143863,0.0006798376,0.001355083,0.000005999391,0.0006438543,0.0002835667,0.007468659,0.02497609],"study_design_scores_gemma":[0.9610438,0.002161046,0.0001018513,0.001044456,0.0005171342,0.0002008897,0.001113998,0.0007759144,0.0004400836,0.0003490258,0.03196209,0.0002897564],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9679716,0.005274333,0.0001139306,0.01224618,0.001276076,0.007258178,0.00002750119,0.0004436017,0.005388661],"genre_scores_gemma":[0.9818471,0.000551358,0.0008441419,0.003467083,0.002324394,0.001032815,0.0004715046,0.00008721444,0.009374409],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02468633,"threshold_uncertainty_score":0.9607245,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01863339277844512,"score_gpt":0.3402666791115156,"score_spread":0.3216332863330705,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}